for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Principal Investigator
by Collin Blakely
Photo of Collin Blakely
Collin Blakely



The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.

Official Title

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer


Glesatinib is an orally administered multi-targeted tyrosine kinase inhibitor (TKI) that primarily targets the Axl and Mesenchymal-Epithelial Transition (MET) receptors. Sitravatinib is an orally-available, potent small molecule inhibitor of a closely related spectrum of receptor tyrosine kinases (RTKs) including MET, Axl, MERTK, VEGFR family, PDGFR family, KIT, FLT3, Trk family, RET, DDR2 and selected Eph family members. Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. Nivolumab is a human IgG monoclonal antibody that binds to the programmed cell death-1(PD-1) receptor and blocks its interaction with programmed cell death ligand-1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response including anti-tumor immune response. Combining an immunotherapeutic PD-L1 checkpoint inhibitor with an agent that has both immune modulatory and antitumor properties could enhance the antitumor efficacy observed with either agent alone. The study will begin with a lead-in dose escalation evaluation of two dose levels of each investigational agent in combination with nivolumab. Following completion of the lead-in dose escalation, enrollment into the Phase 2 study will proceed.


Carcinoma, Non-Small-Cell Lung Nivolumab Mocetinostat Glesatinib Sitravatinib Glesatinib and Nivolumab Sitravatinib and Nivolumab Mocetinostat and Nivolumab


You can join if…

Open to people ages 18 years and up

  • Diagnosis of non-small cell lung cancer.
  • Prior treatment with a checkpoint inhibitor (as appropriate per cohort)
  • Adequate bone marrow and organ function

You CAN'T join if...

  • Uncontrolled tumor in the brain
  • Unacceptable toxicity with prior checkpoint inhibitor
  • Impaired heart function


  • University of California San Francisco Comprehensive Cancer Center
    San Francisco California 94115 United States
  • University of California Los Angeles - Torrance - Community Cancer Care
    Santa Clarita California 91355 United States

Lead Scientist at UCSF

  • Collin Blakely
    Dr. Blakely is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program.


in progress, not accepting new patients
Start Date
Completion Date
Mirati Therapeutics Inc.
Phase 2
Study Type
Last Updated